ES2661812T3 - Composiciones - Google Patents

Composiciones Download PDF

Info

Publication number
ES2661812T3
ES2661812T3 ES10824162.1T ES10824162T ES2661812T3 ES 2661812 T3 ES2661812 T3 ES 2661812T3 ES 10824162 T ES10824162 T ES 10824162T ES 2661812 T3 ES2661812 T3 ES 2661812T3
Authority
ES
Spain
Prior art keywords
omega
emulsion
weight
fatty acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10824162.1T
Other languages
English (en)
Spanish (es)
Inventor
Omar Abdelfattah Abu-Baker
Donald Colin Mackenzie
Rennan Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mochida Pharmaceutical Co Ltd
Original Assignee
Mochida Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharmaceutical Co Ltd filed Critical Mochida Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2661812T3 publication Critical patent/ES2661812T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/01—Other fatty acid esters, e.g. phosphatides
    • A23D7/011—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/015—Reducing calorie content; Reducing fat content, e.g. "halvarines"
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Edible Oils And Fats (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES10824162.1T 2009-10-16 2010-10-15 Composiciones Active ES2661812T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25231009P 2009-10-16 2009-10-16
US252310P 2009-10-16
US26769709P 2009-12-08 2009-12-08
US267697P 2009-12-08
PCT/US2010/052840 WO2011047259A1 (en) 2009-10-16 2010-10-15 Compositions

Publications (1)

Publication Number Publication Date
ES2661812T3 true ES2661812T3 (es) 2018-04-04

Family

ID=43876577

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10824162.1T Active ES2661812T3 (es) 2009-10-16 2010-10-15 Composiciones

Country Status (5)

Country Link
US (3) US9717703B2 (enExample)
EP (1) EP2488022B1 (enExample)
JP (6) JP5951489B2 (enExample)
ES (1) ES2661812T3 (enExample)
WO (1) WO2011047259A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
AU2010222648B2 (en) 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
WO2011048493A1 (en) * 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
CA2993690C (en) 2010-01-19 2022-03-22 Dsm Ip Assets B.V. Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
US9585837B2 (en) * 2010-04-09 2017-03-07 Dsm Ip Assets B.V. Thermally stable oil-in-water emulsions containing an oil that contains polyunsaturated fatty acids
EP2613767A4 (en) * 2010-09-08 2014-03-19 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a free fatty acid, and a statin
EP2613766A4 (en) * 2010-09-08 2014-04-09 Pronova Biopharma Norge As COMPOSITIONS COMPRISING AN OIL MIXTURE CONSISTING OF FATTY ACIDS COMPRISING EPA AND DHA AS FREE ACID, SURFACTANT AND STATIN
WO2012037365A1 (en) * 2010-09-16 2012-03-22 Quest Diagnostics Investments Incorporated Mass spectrometric determination of eicosapentaenoic acid and docosahexaenoic acid
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
DE102011050493A1 (de) 2011-05-19 2012-11-22 Ludwig-Maximilians-Universität München Vorrichtung und Verfahren zur Detektion der Auslenkung elastischer Elemente
EA035287B1 (ru) * 2011-07-21 2020-05-25 ДСМ АйПи АССЕТС Б.В. Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
AU2013240427B2 (en) 2012-03-30 2017-08-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
BR112014032905B1 (pt) 2012-06-29 2022-02-22 Amarin Pharmaceuticals Ireland Limited Uso de éster etílico do ácido eicosapentaenóico para redução do risco de morte cardiovascular, revascularização coronária e/ou angina instável em um indivíduo em terapia com estatina
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
CN111888343A (zh) * 2013-07-18 2020-11-06 持田制药株式会社 ω-3脂肪酸的自乳化组合物
JPWO2015008849A1 (ja) * 2013-07-18 2017-03-02 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
WO2015011724A2 (en) * 2013-07-22 2015-01-29 Kms Health Center Pvt Ltd A novel omega -3 fatty acid composition with a plant extract
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016117057A1 (ja) 2015-01-21 2016-07-28 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
AR105674A1 (es) * 2016-08-11 2017-10-25 Consejo Nac De Investigaciones Científicas Y Técnicas (Conicet) Una nanoemulsión comestible de aceite de chía
AU2017301077B2 (en) * 2016-08-12 2022-07-07 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
IL268457B (en) 2019-08-04 2022-05-01 Omega 3 Galilee Ltd Oil- suspension of edible solids and methods of preparing the same
CN114980973A (zh) 2019-11-12 2022-08-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
US20230113738A1 (en) * 2020-03-06 2023-04-13 Optimega Llc Fatty acid compositions for enteral use
KR102736482B1 (ko) * 2020-06-26 2024-11-28 건국대학교 산학협력단 나노에멀젼이 포함된 육류 제품 및 이의 제조방법
JP2021008518A (ja) * 2020-10-21 2021-01-28 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
IL289782B (en) * 2022-01-12 2022-07-01 Omega 3 Galilee Ltd Oil- suspension of edible solids and methods of preparing the same

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096258A (en) 1974-12-16 1978-06-20 Par-Way Mfg. Co. Method for preparing a stable clear liquid release agent
US4192898A (en) 1975-10-10 1980-03-11 Par-Way Mfg Co. Stable clear liquid release agent and method for preparation
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
US4665098A (en) 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
JPS63101320A (ja) 1986-10-17 1988-05-06 Dainippon Pharmaceut Co Ltd バルプロ酸カルシウム製剤
NZ224497A (en) 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
WO1991018613A1 (en) 1990-06-01 1991-12-12 Research Corporation Technologies, Inc. Self-emulsifying glasses
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
DE69216836T2 (de) 1991-07-26 1997-06-12 Smithkline Beecham Corp W/o mikroemulsionen
EP0573978B1 (en) 1992-06-12 1999-04-21 Kao Corporation Bath additive composition comprising surfactant-containing seamless capsules and method for producing the capsules.
DK88692D0 (da) 1992-07-06 1992-07-06 Danochemo As Fremgangsmaade til fremstilling af mikrokapsler
JPH0649479A (ja) 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
JP3405746B2 (ja) 1992-10-28 2003-05-12 フロイント産業株式会社 シームレスカプセルの製造方法
JPH06298642A (ja) * 1993-04-14 1994-10-25 Japan Tobacco Inc 高度不飽和脂肪酸含有ｏ／ｗ型乳剤及びその酸化防止方法
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405041D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel process
FR2729307B1 (fr) 1995-01-18 1997-04-18 Seppic Sa Utilisation d'esters d'acides gras ethoxyles comme composants auto-emulsionnables notamment utiles pour la preparation de produits de traitement phytosanitaires ou de medicaments a usage veterinaire ou humain
WO1996033697A1 (fr) 1995-04-24 1996-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulation auto-emulsionnable formant une emulsion huile dans l'eau
JP3759986B2 (ja) 1995-12-07 2006-03-29 フロイント産業株式会社 シームレスカプセルおよびその製造方法
ES2174462T3 (es) 1997-07-29 2002-11-01 Upjohn Co Formulacion autoestimulante para compuestos lipofilos.
DK0989851T3 (da) 1997-07-29 2003-01-27 Upjohn Co Selvemulgerende formulering indeholdende sure lipofile forbindelser
US5972182A (en) 1997-12-05 1999-10-26 Ceramphysics, Inc. Electrode composition and application method for oxygen generators
ATE497384T1 (de) * 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
AU3843999A (en) 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
WO2001028519A1 (de) 1999-10-20 2001-04-26 Vesifact Ag Mikroemulsion-prekonzentrate und mikroemulsionen
JP2001152179A (ja) 1999-11-30 2001-06-05 Takasago Internatl Corp 香味持続型粉末香料の調製方法
US20020102301A1 (en) 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US20050037073A1 (en) 2000-01-13 2005-02-17 Alpharx Inc. Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
KR100393478B1 (ko) 2000-03-29 2003-08-06 주식회사종근당 자가유화 매트릭스형 경점막·경피흡수제제
DE60109295T2 (de) 2000-07-24 2006-04-13 Sugen, Inc., South San Francisco Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
EP1339429A4 (en) 2000-11-29 2007-03-14 Smithkline Beecham Corp COMPOSITION CONTAINING STATINS AND CALCIUM FOR IMPROVING CARDIOVASCULAR HEALTH
KR100426346B1 (ko) 2000-11-30 2004-04-08 한국화학연구원 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용약제 조성물
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
GB0101198D0 (en) 2001-01-17 2001-02-28 Scherer Technologies Inc R P Ingestible compositions containing an odoriferous oil
US20040081670A1 (en) * 2001-02-11 2004-04-29 Dariush Behnam Method for producing an active ingredient concentrate, and an active ingredient concentrate
US20030105141A1 (en) 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
AUPR573001A0 (en) 2001-06-15 2001-07-12 Glaxo Wellcome Australia Ltd Lymphatic drug delivery system
US20040018248A1 (en) 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
NO20021592D0 (no) 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
IL164163A0 (en) 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
EP1531687A4 (en) * 2002-06-18 2006-11-15 Martek Biosciences Corp STABLE EMULSION OF LEN IN WATER SOLUTIONS AND METHOD FOR THE PRODUCTION THEREOF
JP4417039B2 (ja) 2002-06-28 2010-02-17 太陽化学株式会社 水中油滴型乳化組成物
CN1166368C (zh) 2003-02-26 2004-09-15 刘威 海狗油脂肪乳注射液、其制备方法及其在制备静脉注射剂中的应用
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20040185068A1 (en) 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
WO2004098544A1 (ja) 2003-05-09 2004-11-18 The Nisshin Oillio Group, Ltd. 自己乳化型油性液状化粧料
WO2005037251A1 (en) 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self-emulsifying drug delivery systems for hydrophobic therapeutic compounds
WO2005037250A1 (en) 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self emulsifying drug delivery systems for hydrophobic therapeutic compounds
ES2235642B2 (es) 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
US7022713B2 (en) 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
WO2005105040A2 (en) 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
FR2873585B1 (fr) 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
ATE439049T1 (de) 2004-07-22 2009-08-15 Aquanova Ag Solubilisate von ätherischen ölen und anderen stoffen
AU2005271413A1 (en) 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Novel statin pharmaceutical compositions and related methods of treatment
CA2577345C (en) 2004-08-18 2013-02-19 Hiroki Ueshima Jelly composition
US20060051462A1 (en) 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
US20080311207A1 (en) 2004-09-08 2008-12-18 Manoj Varshney Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
US20060088574A1 (en) 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
KR101356335B1 (ko) 2004-12-06 2014-02-06 릴라이언트 파마슈티컬스 인코퍼레이티드 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
US20060211763A1 (en) 2005-03-08 2006-09-21 Abdel Fawzy Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
CN1853728A (zh) 2005-04-19 2006-11-01 上海天博生物科技有限公司 一种改善药物或营养物口服吸收的方法、配方及其应用
US20060292217A1 (en) 2005-06-03 2006-12-28 Schmidt Robbin D Nutritional supplement and soft gelatin capsule delivery system
US20070031538A1 (en) 2005-07-13 2007-02-08 Gul Konuklar Liquid nutritional compositions containing n-3 polyunsaturated fatty acids
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
US9743680B2 (en) 2005-10-14 2017-08-29 Wild Flavors, Inc. Microemulsions for use in food and beverage products
CN101360481A (zh) 2005-11-22 2009-02-04 雀巢技术公司 水包油乳液及其用于功能性输送的用途
US20090012157A1 (en) 2006-02-06 2009-01-08 Sears Barry D Sesamol Derivatives as Novel Inhibitors of Arachidonic Acid Formation
WO2007103186A2 (en) 2006-03-03 2007-09-13 Fmc Corporation Method and apparatus for the preparation of capsules
MY153288A (en) 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
US20080058418A1 (en) 2006-09-06 2008-03-06 The Coca-Cola Company Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
KR100835250B1 (ko) 2006-09-07 2008-06-09 주식회사 바이오랜드 자기유화 전달체 및 이의 제조방법
JP2008178341A (ja) * 2007-01-24 2008-08-07 Taiyo Kagaku Co Ltd 多価不飽和脂肪酸含有組成物
WO2008101344A1 (en) * 2007-02-22 2008-08-28 Peter Tomlinson Soluble bioactive lipophilic compounds compositions
CA2677670C (en) 2007-03-20 2010-08-03 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
JP5135852B2 (ja) 2007-03-30 2013-02-06 日油株式会社 可溶化用組成物
AR060847A1 (es) 2007-05-03 2008-07-16 Spannagel Lucia Antonia Formulacion a base de calendula, aloe y centella.
US20100196456A1 (en) 2007-05-09 2010-08-05 Daniel Strasser Emulsion preconcentrates and micellar formulations containing wood resins
CN103190631B (zh) 2008-03-20 2016-01-20 维尔恩公司 非水性预乳液组合物及制备包含植物甾醇的饮料的方法
AU2009226019C1 (en) * 2008-03-20 2014-02-20 Virun, Inc. Emulsions including a PEG-derivative of tocopherol
US8337931B2 (en) 2008-06-23 2012-12-25 Virun, Inc. Compositions containing non-polar compounds
JP2010155799A (ja) 2008-12-26 2010-07-15 Fujifilm Corp 粉末組成物及びそれを含む食品
AU2010222648B2 (en) 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
WO2011048493A1 (en) 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture

Also Published As

Publication number Publication date
EP2488022B1 (en) 2018-01-10
JP6728303B2 (ja) 2020-07-22
US9717703B2 (en) 2017-08-01
JP2013508296A (ja) 2013-03-07
US20120207800A1 (en) 2012-08-16
JP6430608B2 (ja) 2018-11-28
EP2488022A1 (en) 2012-08-22
JP2016222672A (ja) 2016-12-28
JP5951489B2 (ja) 2016-07-13
JP2022095815A (ja) 2022-06-28
JP2018048163A (ja) 2018-03-29
JP2019031555A (ja) 2019-02-28
US20170304249A1 (en) 2017-10-26
US20200246299A1 (en) 2020-08-06
US10668038B2 (en) 2020-06-02
JP7055840B2 (ja) 2022-04-18
WO2011047259A1 (en) 2011-04-21
JP2020180132A (ja) 2020-11-05
EP2488022A4 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
ES2661812T3 (es) Composiciones
JP7621450B2 (ja) ω３脂肪酸の自己乳化組成物
AU2011201503B2 (en) Dietary supplement composition for blood lipid health
US20210186870A1 (en) Improved cannabinoid bioavailability
Perlman et al. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib
US20210059949A1 (en) Modified release composition comprising a cannabinoid
EP2490678B1 (en) Coated capsules and tablets of a fatty acid oil mixture
US20100240753A1 (en) Effective pharmaceutical carrier for poorly bioavailable drugs
Mohsin et al. Lipid based self emulsifying formulations for poorly water soluble drugs-an excellent opportunity
MX2011002640A (es) Capsula de polisacarido que comprende una emulsion que contiene aceite de acido graso.
CN105246460A (zh) 消旋卡多曲类脂组合物
JP2015522031A (ja) ラセカドトリル脂質組成物
EP3468535B1 (en) Resveratrol solubilisation product for pharmaceutical purposes
US9861605B2 (en) Enriched injectable emulsion containing selected fatty acid triglycerides
US8062690B2 (en) Dietary supplement composition for blood lipid health
EP3503926B1 (en) New improved composition of racecadotril
JP2017500355A (ja) ラセカドトリル組成物
UA112845C2 (uk) Склад 14-eпi-аналогів вітаміну d